摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,4-二氢-2H-1,4-苯并嗪-2-甲胺 | 102908-68-9

中文名称
3,4-二氢-2H-1,4-苯并嗪-2-甲胺
中文别名
1-(3,4-二氢-2H-1,4-苯并噁嗪-2-基)甲胺
英文名称
(3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methanamine
英文别名
3,4-dihydro-2H-1,4-benzoxazin-2-ylmethanamine
3,4-二氢-2H-1,4-苯并嗪-2-甲胺化学式
CAS
102908-68-9
化学式
C9H12N2O
mdl
——
分子量
164.207
InChiKey
IGINVTLDGILHIM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    312.2±31.0 °C(Predicted)
  • 密度:
    1.108±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    47.3
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2934999090

SDS

SDS:f5535e9b889485bd4a08c255d54999be
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (2S,4R)-4-hydroxy-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxylic acid3,4-二氢-2H-1,4-苯并嗪-2-甲胺N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 1.0h, 以60%的产率得到(2S,4R)-N-((3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methyl)-4-hydroxy-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxamide
    参考文献:
    名称:
    Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase
    摘要:
    本发明涉及双功能化合物,其作为靶向泛素化的调节剂具有实用性,特别是作为本发明的双功能化合物对各种被降解和/或受到抑制的多肽和其他蛋白质的抑制剂。具体而言,本发明涉及含有一端结合泛素连接酶的VHL配体,另一端结合靶蛋白的基团的化合物,使得靶蛋白靠近泛素连接酶以促使该蛋白的降解(和抑制)。本发明展示了与本发明化合物相关的广泛的药理活性范围,与靶向多肽的降解/抑制一致。
    公开号:
    US20140356322A1
  • 作为产物:
    描述:
    3,4-二氢-2H-4-苯并噁嗪-2-羧酰胺 在 lithium aluminium tetrahydride 作用下, 以 四氢呋喃 为溶剂, 反应 36.0h, 以68%的产率得到3,4-二氢-2H-1,4-苯并嗪-2-甲胺
    参考文献:
    名称:
    New Substituted 1,4-Benzoxazine Derivatives with Potential Intracellular Calcium Activity
    摘要:
    Substituted 1,4-benzoxazines bearing an amino side chain at the 2-position were prepared and were found to have a moderate activity on intracellular calcium. Of the compounds studied it was found that those which possess a homoveratrylamino moiety exhibited superior potency. The chain length and the nature of the amine (4-fluorophenylpiperazine, 4-fluorobenzhydryloxyethylamine, N-substituted homoveratrylamine) is discussed. The 4-benzyl-3,4-dihydro-2[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-2H-1,4-benzoxazine (3c) is the most potent derivative of the series with a ratio of IC50 values against PE (phenylephrine) and K+ of 2.1. Under these test conditions a ratio near 1 indicates potential intracellular calcium activity while a ratio greater than 100 an action on extracellular calcium influx.
    DOI:
    10.1021/jm970795t
点击查看最新优质反应信息

文献信息

  • [EN] NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS DE BENZYLSULFONAMIDE UTILES EN TANT QU'INHIBITEURS DE MOGAT-2
    申请人:LILLY CO ELI
    公开号:WO2014074365A1
    公开(公告)日:2014-05-15
    The present invention provides compounds of Formula I. Wherein Rl, L, and A are as described herein, or a pharmaceutical salt thereof, processes for preparing the compounds, and methods of treating a condition, such as hypertriglyceridemia, using the compounds.
    本发明提供了式I的化合物。其中R1、L和A如本文所述,或其药用盐,制备该化合物的方法,以及使用该化合物治疗高甘油三酯血症等疾病的方法。
  • [EN] MORPHOLINYLMETHYLUREAS CCR-3 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR DE MORPHOLINYLMETHYLUREE CCR-3
    申请人:GLAXO GROUP LTD
    公开号:WO2003097618A1
    公开(公告)日:2003-11-27
    Compounds of formula (I'): (I); wherein: R1 represents substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; X represents -(CRkaRkb)k-; Rka and Rkb are each independently hydrogen or C1-6alkyl; k is 0-5; Y represents -NR3- or a bond; R3 represents hydrogen or C1-6alkyl; Z represents a moiety of formula (ZA), (ZB), (ZC), (ZD), (ZE), or (ZF); A represents -(CRjaRjb)j-; Rja and Rjb are each independently hydrogen or C1-6alkyl; j is 0, 1 or 2, and; R2 represents unsubstituted or substituted aryl; and salts and solvates thereof are CCR3 receptor antagonists and are thus indicated to be useful in therapy.
    公式(I')的化合物:(I); 其中:R1代表取代或未取代的芳基或取代或未取代的杂环芳基; X代表-(CRkaRkb)k-; Rka和Rkb分别独立地表示氢或C1-6烷基; k为0-5; Y表示-NR3-或键; R3表示氢或C1-6烷基; Z表示公式(ZA)、(ZB)、(ZC)、(ZD)、(ZE)或(ZF)的基团; A表示-(CRjaRjb)j-; Rja和Rjb分别独立地表示氢或C1-6烷基; j为0、1或2,且; R2表示未取代或取代的芳基; 其盐和溶剂化物为CCR3受体拮抗剂,因此被认为在治疗中有用。
  • [EN] NOVEL DERIVATIVES OF ARYL-{4-HALOGENO-4-[AMINOMETHYL]-PIPERIDIN-1-YL}-METHANONE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS<br/>[FR] NOUVEAUX DÉRIVÉS DE L'ARYL-{4-HALOGÉNO-4-[AMINOMÉTHYLE]-PIPÉRIDIN-1-YLE}-MÉTHANONE, LEUR PROCÉDÉ DE PRÉPARATION ET LEUR UTILISATION EN TANT QUE PRODUITS MÉDICINAUX
    申请人:PF MEDICAMENT
    公开号:WO2010139758A1
    公开(公告)日:2010-12-09
    The present invention concerns compounds of general formula (1) (I) wherein R1 is: - a hydrogen atom, or a halogen, - a straight or branched C1-C6 alkyl group or a C1-C3 fluoroalkyl group, - a straight or branched C1-C6 alcoxy group, a carbamyl group, N-substituted or not by one or two, straight or branched C1-C3 alkyl groups, or - a cyano group (CN) R2 is: - a hydrogen atom or a straight or branched C1-C6 alkyl group, HaI1, Hal2 and Hal3 are: - a halogen their addition salts and the hydrates of addition salts with pharmaceutically acceptable mineral acids or organic acids, and their enantiomer forms.
    本发明涉及一般式(1)(I)的化合物,其中R1是:- 氢原子,或卤素,- 直链或支链C1-C6烷基或C1-C3氟烷基,- 直链或支链C1-C6醇基,氨基甲酰基,N-取代或未取代一个或两个,直链或支链C1-C3烷基的氨基甲酰基,或- 氰基(CN)R2是:- 氢原子或直链或支链C1-C6烷基,HaI1,Hal2和Hal3是:- 卤素,它们的加合物盐和与药用可接受的无机酸或有机酸的加合物盐的水合物,以及它们的对映体形式。
  • NOVEL DERIVATIVES OF ARYL--METHANONE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS
    申请人:Vacher Bernard
    公开号:US20120115860A1
    公开(公告)日:2012-05-10
    The present invention concerns compounds of general formula (1) (I) wherein R 1 is: a hydrogen atom, or a halogen, a straight or branched C 1 -C 6 alkyl group or a C 1 -C 3 fluoroalkyl group, a straight or branched C 1 -C 6 alcoxy group, a carbamyl group, N-substituted or not by one or two, straight or branched C 1 -C 3 alkyl groups, or a cyano group (CN) R2 is: a hydrogen atom or a straight or branched C 1 -C 6 alkyl group, HaI 1 , Hal 2 and Hal 3 are: a halogen their addition salts and the hydrates of addition salts with pharmaceutically acceptable mineral acids or organic acids, and their enantiomer forms.
    本发明涉及一般式(1)(I)的化合物,其中R1为:氢原子,或卤素,直链或支链C1-C6烷基或C1-C3氟烷基,直链或支链C1-C6烷氧基,氨基甲酰基,由一或两个直链或支链C1-C3烷基取代或未取代的N-取代基,或氰基(CN)。R2为:氢原子或直链或支链C1-C6烷基,HaI1,Hal2和Hal3为:卤素,它们的加成盐和与药学上可接受的无机酸或有机酸的加成盐的水合物,以及它们的对映异构体形式。
  • NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS
    申请人:ELI LILLY AND COMPANY
    公开号:US20150284404A1
    公开(公告)日:2015-10-08
    The present invention provides compounds of Formula I. Wherein R1, L, and A are as described herein, or a pharmaceutical salt thereof, processes for preparing the compounds, and methods of treating a condition, such as hypertriglyceridemia, using the compounds.
    本发明提供了公式I的化合物。其中R1,L和A如此描述,或其药用盐,制备所述化合物的方法,以及使用所述化合物治疗高甘油三酯血症等疾病的方法。
查看更多